Matthew Reed
Educational Degrees
FATS - Fellow Academy of Toxicological Sciences, DABT - Diplomate American Board of Toxicology
- PhD, Pharmacology and Toxicology, Texas A&M University, 1997
- Postdoctoral Fellow, UTMD Anderson, 1997-1998
- Postdoctoral Fellow, University of New Mexico College of Pharmacy, 1998- 1999

-BA Biology, Texas A&M University, 1992
Agricultural Chemicals/Pesticides, Biologics/Biotherapeutics/Biotechnology, Chemical Warfare Agents, Drug/Pharmaceutical Development, Environmental (Air- Water- Terrestrial) Toxicology, Expert Witnessing, Formulations, GLP Study Auditing, Hazard Communication, Inhalation and Respiratory Toxicology, Pharmacokinetics/Toxicokinetics, Product Safety Assessment, Regulatory Toxicology
Inhalation, Respiratory, Inhaled Drug Development, Inhaled Drugs, Inhaled Pharmaceuticals, Inhaled Biologics, Vaccines, CBRNE, Due Diligence, General Toxicology, Pharma R&D, SBIR Development, Government Grants and Contracts, Air Pollution, PMN, TSCA, FIFRA, Pulmonary Disease, Pharmacology, Animal Models, GLP, IND, NDA, BLA, Gene Therapy, Immunooncology
Matt Reed is Principal, Coelus ( where he facilitates early to late phase development of pharmaceutical IP and provides consulting services in integrated drug development strategies, toxicology, pharmacology, and hazard assessment. Dr. Reed is a pharmacologist, board certified toxicologist, ABT Board Member, and Fellow of the Academy of Toxicological Sciences. His current consulting activities include inhaled pharmacology and toxicology program design, due diligence review, SBIR development, regulatory document development and review, inhaled hazard assessment (PMN), inhaled vaccines program development, gene therapy program development, IBS program review, respiratory disease program development (asthma, fibrosis, PAH, infectious diseases, CF, etc.), RNA/ oligo program development, etc. Dr. Reed is former VP, Applied Toxicology and Nonclinical Development at Lovelace. Here he focused on applied toxicology questions, ag-chem industry initiatives, pharmaceutical IP development, and pharmaceutical R&D. He was a strategic leader and member of Senior Management Teams, 2007-2017. From 2000-2009 he served as the line manager of the GLP Toxicology Pharma Division (building the division from inception) and served as study director for the largest ($20M+) inhaled source pollutant toxicology program ever performed. He has been a part of successful R&D programs that that have transitioned to IND, NDA and other regulatory registration milestones for small molecules, biologics, oligonucleotides, and alternative fuel additives. Dr. Reed has developed large scale hazard assessment programs, Integrated Drug Development Plans and timelines, and has developed hundreds of safety and pharmacology programs for R&D initiatives. Specifically he has overseen and consulted on initiatives to include toxicant/ drug delivery, applied toxicology studies, formulation/device feasibility and development, pharmacokinetics, pharmacology, safety pharmacology, pivotal IND and NDA GLP compliant studies, etc. Dr. Reed has been an awardee, PI/ Co-PI, or subcontract PI of over $52M in federal R&D grants and contracts for drugs and vaccines (delivery by multiple routes) working with government funded commercial firms, NIH, BARDA and DOD to develop pharmaceutics for clinical indications as well as combat, homeland, and defense security threats.

- Principle, Coelus LLC, Current
- Senior Scientist, VP Applied Toxicology and Nonclinical Development, Lovelace Biomedical/ Lovelace Respiratory Research Institute, Previous
- Senior Toxicologist, Alcon Research Limited, Former
9408 Allande Rd NE
Zip Code
Mobile Number